MX2020006937A - Inmunógenos peptídicos y formulaciones de estos dirigidos a la ige unida a la membrana para el tratamiento de enfermedades alérgicas mediadas por ige. - Google Patents

Inmunógenos peptídicos y formulaciones de estos dirigidos a la ige unida a la membrana para el tratamiento de enfermedades alérgicas mediadas por ige.

Info

Publication number
MX2020006937A
MX2020006937A MX2020006937A MX2020006937A MX2020006937A MX 2020006937 A MX2020006937 A MX 2020006937A MX 2020006937 A MX2020006937 A MX 2020006937A MX 2020006937 A MX2020006937 A MX 2020006937A MX 2020006937 A MX2020006937 A MX 2020006937A
Authority
MX
Mexico
Prior art keywords
ige
formulations
immunogen constructs
mediated allergic
peptide immunogen
Prior art date
Application number
MX2020006937A
Other languages
English (en)
Inventor
Chang Yi Wang
Feng Lin
Jiun Bo Chen
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Publication of MX2020006937A publication Critical patent/MX2020006937A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción se refiere a construcciones de inmunógenos peptídicos EMPD de IgE y formulaciones de estas para el tratamiento de enfermedades alérgicas mediadas por IgE. Las construcciones de inmunógenos peptídicos EMPD de IgE tienen un péptido de epítopo de linfocitos B de más de 20 aminoácidos, preferentemente cíclicos, unidos a través de un espaciador opcional a epítopos de linfocitos T auxiliares (Th) heterólogos derivados de proteínas patógenas. Estas construcciones de inmunógenos peptídicos y sus formulaciones pueden estimular la generación de anticuerpos altamente específicos en hospedadores vacunados que se dirigen contra el péptido EMPD de IgE y reaccionan de forma cruzada con IgE unida a la membrana en linfocitos B comprometidos con la secreción de IgE. Los anticuerpos inducidos por las construcciones de inmunógenos peptídicos y las formulaciones de estas en hospedadores vacunados pueden inducir la apoptosis de los linfocitos B que expresan IgE y mediar en la citotoxicidad celular dependiente de anticuerpos (ADCC), lo que genera la reducción de los niveles de IgE específica del antígeno e IgE total en hospedadores vacunados para tratar eficazmente la patología alérgica mediada por IgE.
MX2020006937A 2017-12-31 2017-12-31 Inmunógenos peptídicos y formulaciones de estos dirigidos a la ige unida a la membrana para el tratamiento de enfermedades alérgicas mediadas por ige. MX2020006937A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2017/069174 WO2019133024A1 (en) 2017-12-31 2017-12-31 Peptide immunogens and formulations thereof targeting membrane-bound ige for treatment of ige mediated allergic diseases

Publications (1)

Publication Number Publication Date
MX2020006937A true MX2020006937A (es) 2020-10-05

Family

ID=67068075

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006937A MX2020006937A (es) 2017-12-31 2017-12-31 Inmunógenos peptídicos y formulaciones de estos dirigidos a la ige unida a la membrana para el tratamiento de enfermedades alérgicas mediadas por ige.

Country Status (13)

Country Link
US (1) US20230270848A1 (es)
EP (1) EP3731934A1 (es)
JP (1) JP7239203B2 (es)
KR (1) KR20200115522A (es)
CN (1) CN111565801B (es)
AU (1) AU2017445171A1 (es)
BR (1) BR112020013352A2 (es)
CA (1) CA3087036A1 (es)
MX (1) MX2020006937A (es)
RU (1) RU2769983C2 (es)
SG (1) SG11202006215TA (es)
TW (1) TWI804553B (es)
WO (1) WO2019133024A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021150910A1 (en) * 2020-01-23 2021-07-29 Ubi Ip Holdings Peptide immunogens targeting pituitary adenylate cyclase-activating peptide (pacap) and formulations thereof for prevention and treatment of migraine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0787150A1 (en) * 1994-10-25 1997-08-06 United Biomedical, Inc. SYNTHETIC IgE MEMBRANE ANCHOR PEPTIDE IMMUNOGENS FOR THE TREATMENT OF ALLERGY
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
CA2421274A1 (en) 2000-09-06 2002-03-14 Pharmexa A/S Method for down-regulating ige
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
AU2003243663A1 (en) * 2002-06-20 2004-01-06 The Trustees Of The University Of Pennsylvania Vaccines for suppressing ige-mediated allergic disease and methods for using the same
PL2401300T3 (pl) * 2009-02-25 2018-07-31 Academia Sinica Przeciwciała anty-C[epsilon]mX zdolne do wiązania z ludzkim mIgE na limfocytach B
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type

Also Published As

Publication number Publication date
SG11202006215TA (en) 2020-07-29
RU2020125383A3 (es) 2022-01-31
RU2769983C2 (ru) 2022-04-12
AU2017445171A1 (en) 2020-08-13
CN111565801A (zh) 2020-08-21
KR20200115522A (ko) 2020-10-07
JP7239203B2 (ja) 2023-03-14
JP2021515744A (ja) 2021-06-24
WO2019133024A1 (en) 2019-07-04
CA3087036A1 (en) 2019-07-04
TWI804553B (zh) 2023-06-11
RU2020125383A (ru) 2022-01-31
EP3731934A1 (en) 2020-11-04
BR112020013352A2 (pt) 2020-12-01
US20230270848A1 (en) 2023-08-31
CN111565801B (zh) 2023-11-10
TW201930346A (zh) 2019-08-01

Similar Documents

Publication Publication Date Title
AU2019283892A1 (en) Anti-human papillomavirus 16 E7 T cell receptors
MX2019005268A (es) Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer.
CL2021000636A1 (es) Vacuna contra el virus de la peste porcina africana
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
MX2021010519A (es) Proteinas f de rsv de prefusion y su uso.
MX2019015742A (es) Receptores de celulas t novedosos, e inmunoterapia usando los mismos.
MX2019006349A (es) Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
WO2010104749A8 (en) Antigen presenting cell targeted cancer vaccines
MX2014000749A (es) Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
MX2011009438A (es) Anticuerpos anti-cd40 y usos de los mismos.
AR078693A1 (es) Vacunas dirigidas contra celulas presentadoras de antigenos
MX2012003058A (es) Vacunas dirigidas a celulas de langerhans.
MX2019015286A (es) Inmunogenos peptidicos del extremo c-terminal de proteinas alfa-sinucleinas y formulaciones de las mismas para el tratamiento de sinucleinopatias.
MY188083A (en) Recombinant proteins and their therapeutic uses
ZA202104213B (en) Antibodies that neutralize hepatitis b virus and uses thereof
EA201591796A1 (ru) Антитела к cd52
MX2020006937A (es) Inmunógenos peptídicos y formulaciones de estos dirigidos a la ige unida a la membrana para el tratamiento de enfermedades alérgicas mediadas por ige.
AR041086A1 (es) Vacuna
WO2018102774A8 (en) Pneumococcal vaccine combining selected alpha helical domains and proline rich domains of pneumococcal surface protein a
MX2018013523A (es) Anticuerpos monoclonales de adn dirigidos a il-6 y cd126.
JOP20210247A1 (ar) علاج الصداع باستخدام أجسام مضادة لـ cgrp
MX2021007906A (es) Nmunógenos peptídicos dirigidos a la interleucina 6 (il-6) y sus formulaciones para la inmunoterapia de enfermedades afectadas por la desregulación de la il-6.
MX2020008062A (es) Constructos de ácido nucleico de anticuerpos para usar contra el virus sincicial respiratorio.
EA202091435A1 (ru) Оптимизированная система вектор-хозяин для получения защитной моно- и поливалентной субъединичной вакцины на основе дрожжей kluyveromyces lactis
AR111380A1 (es) Tratamiento para el asma con anticuerpo anti-tslp